Get the Stockscreener App
7.60
0.98%
-0.075
After Hours:
7.56
-0.04
-0.53%
Sagimet Biosciences Inc stock is traded at $7.60, with a volume of 476.86K.
It is down -0.98% in the last 24 hours and up +12.43% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.675
Open:
$7.81
24h Volume:
476.86K
Relative Volume:
0.77
Market Cap:
$235.61M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-6.4081
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+3.97%
1M Performance:
+12.43%
6M Performance:
+229.00%
1Y Performance:
+76.33%
1-Day Range:
$7.535
$7.87
1-Week Range:
$7.1145
$8.76
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.60 | 249.60M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
What does recent volatility data suggest for Sagimet Biosciences Inc.Quarterly Trade Report & Comprehensive Market Scan Insights - newser.com
Is Sagimet Biosciences Inc. forming a reversal patternJuly 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Will Sagimet Biosciences Inc. (0O2) stock justify high valuationMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Sagimet Biosciences Inc. holders2025 Biggest Moves & Low Risk High Win Rate Picks - newser.com
Sagimet Biosciences Inc. stock retracement – recovery analysisJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Using flow based indicators on Sagimet Biosciences Inc.July 2025 Decliners & Capital Efficient Trade Techniques - newser.com
Has Sagimet Biosciences Inc. found a price floorAnalyst Upgrade & Stock Market Timing Techniques - newser.com
Developing predictive dashboards with Sagimet Biosciences Inc. dataWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ) - Seeking Alpha
Sagimet Biosciences' (SGMT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Sagimet Biosciences Inc. benefit from macro trends2025 Key Lessons & Smart Money Movement Tracker - newser.com
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewswire
≥2‑Stage Fibrosis Improvement: Sagimet denifanstat data to be presented at AASLD 2025 - Stock Titan
Using Ichimoku Cloud for Sagimet Biosciences Inc. technicalsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Why analysts recommend Sagimet Biosciences Inc. (0O2) stock2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Using data tools to time your Sagimet Biosciences Inc. exit2025 Risk Factors & Daily Stock Trend Watchlist - newser.com
Is Sagimet Biosciences Inc. stock ready for a breakoutJuly 2025 Final Week & Low Drawdown Trading Strategies - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Given “Buy” Rating at Canaccord Genuity Group - Defense World
Risk vs reward if holding onto Sagimet Biosciences Inc.Trade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
Has Sagimet Biosciences Inc. formed a bullish divergenceExit Point & Safe Entry Trade Signal Reports - newser.com
Applying big data sentiment scoring on Sagimet Biosciences Inc.Gap Down & Weekly Market Pulse Alerts - newser.com
Canaccord Genuity Maintains Sagimet Biosciences (SGMT) Buy Recommendation - Nasdaq
Canaccord Genuity Group Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat
Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential - TipRanks
Goldman Sachs Group Inc. Sells 109,464 Shares of Sagimet Biosciences Inc. $SGMT - Defense World
Sagimet Biosciences Inc Stock Analysis and ForecastInsider Selling Patterns & Minimal Investment Portfolio Growth - earlytimes.in
Published on: 2025-10-01 08:26:59 - newser.com
Sagimet Biosciences Inc. Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - MarketScreener
Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom - TipRanks
Sagimet Biosciences Initiates Phase 1 Trial for Combination Therapy Targeting Metabolic Dysfunction-Associated Steatohepatitis - Quiver Quantitative
Sagimet Biosciences Announces Dosing of First Participants - GlobeNewswire
Novel MASH Drug Combination: Sagimet Launches Phase 1 Trial for Denifanstat-Resmetirom Treatment - Stock Titan
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - Sahm
Kranti Industries Limited (542459) Expands into New MarketSupport Level Holds & Low Entry Cost Investment - earlytimes.in
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):